GLP-1 Therapy Linked to Nutrient Deficiencies, Requiring Closer Monitoring

Medications like semaglutide and tirzepatide can curb appetite and promote weight loss, but may also limit absorption of essential vitamins and minerals.

Mar. 14, 2026 at 1:18am

Got story updates? Submit your updates here. ›

The rise of medications like semaglutide and tirzepatide has revolutionized weight loss, but a growing body of evidence suggests a potential downside: increased risk of nutrient deficiencies. While these GLP-1 drugs effectively curb appetite and promote weight reduction, they can also inadvertently limit the absorption of essential vitamins and minerals. Healthcare professionals are beginning to adapt their approach to address this issue, including recommending personalized nutrition plans, routine nutrient screening, and targeted supplementation strategies.

Why it matters

Nutrient deficiencies associated with GLP-1 therapy can have serious health consequences, including impacts on muscle mass, bone health, and even hair loss. Proactively addressing these deficiencies is crucial to optimizing treatment outcomes and safeguarding the long-term well-being of patients.

The details

Recent data highlights the extent of the problem, with 12.7% of patients experiencing diagnosed nutrient deficiencies after six months on a GLP-1 receptor agonist, rising to 22.4% after 12 months. Vitamin D deficiency was the most frequently observed, but deficiencies in other key nutrients like fiber, calcium, iron, magnesium, potassium, choline, and vitamins A, C, D, and E are also emerging. Individuals already prone to nutrient deficiencies, such as older adults or those with limited diets, may be at even higher risk.

  • A retrospective analysis revealed that 12.7% of patients experienced diagnosed nutrient deficiencies after six months on a GLP-1 receptor agonist.
  • The rate of diagnosed nutrient deficiencies rose to 22.4% after 12 months on a GLP-1 receptor agonist.

The players

Semaglutide

A GLP-1 receptor agonist medication that effectively curbs appetite and promotes weight reduction.

Tirzepatide

A dual GLP-1/GIP agonist medication that also curbs appetite and promotes weight loss.

Got photos? Submit your photos here. ›

What’s next

The future of GLP-1 therapy will likely involve a more integrated approach that prioritizes nutritional support and proactive monitoring, including personalized nutrition plans, routine nutrient screening, targeted supplementation strategies, enhanced patient education, and integration with telehealth services.

The takeaway

As GLP-1 medications continue to revolutionize weight loss, healthcare providers must remain vigilant in addressing the potential for nutrient deficiencies. A holistic approach that combines personalized nutrition guidance, regular monitoring, and proactive supplementation will be key to optimizing treatment outcomes and safeguarding the long-term health of patients.